TACE combined with RFA and hepatic artery infusion of autologous cytokine-induced killer cells for the treatment of hepatocellular carcinoma: a clinical study
10.3969/j.issn.1008-794X.2017.01.006
- VernacularTitle:TACE联合RFA及自体细胞因子诱导的杀伤细胞肝动脉灌注治疗原发性肝癌的临床研究
- Author:
Jing-Cun SU
1
;
Wei ZHAO
;
Ji-Hong HU
;
Gen-Fa YI
;
Tong WANG
;
Hui-Xia NI
Author Information
1. 650032,昆明医科大学第一附属医院医学影像科
- Keywords:
hepatocellular carcinoma;
transcatheter arterial chemoembolization;
radiofrequency ablation;
autologous cytokine-induced killer cell
- From:
Journal of Interventional Radiology
2017;26(1):24-29
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) and hepatic artery infusion of autologous cytokineinduced killer (CIK) cells in treating clinical stage I hepatocellular carcinoma (HCC).Methods A total of 80 patients with confirmed HCC,who were treated with comprehensive interventional therapy during the period from January 2009 to May 2010,were enrolled in this follow-up study.The patients were divided into the study group (n=38),receiving TACE,RFA and autologous CIK cells therapy,and the control group (n=42),receiving TACE and RFA only.The quality of life (QOL),changes in immune function indexes,progression free survival (PFS) and survival rate were calculated,and the results were compared between the two groups.Results (1) QOL score:after the treatment the QOL score of the study group was significantly higher than that of the control group (P＜0.05).(2) Immune function:the post-treatment immune function values were different from the pre-treatment ones in both groups,the differences were statistically significant (P＜0.05);and the differences between the two groups were also statistically significant (P＜0.05),with the changes of the study group being more obvious.(3) PFS and survival rate:the median PFS of the study group and the control group was 48.0 and 40.1 months respectively,while the one-,2-,3-,5-year survival rates of the study group and the control group were 100％,89.5％,71.1％,55.3％ and 95.2％,88.1％,64.3％,28.6％ respectively.Both the median PFS and survival rate in the study group were higher than those in the control group.Conclusion In treating clinical stage I HCC,TACE combined with RFA and hepatic artery infusion of autologous CIK ceils can improve QOL of patients,strengthen patient's immune function,prolong the median PFS,and increase the overall survival rate.
